COMMENTARY

Top 10 Practice-Changing Articles of 2012: Gastroenterology

David A. Johnson, MD

Disclosures

January 16, 2013

In This Article

Review and Management of Drug Interactions With Boceprevir and Telaprevir

Kiser JJ, Burton JR, Anderson PL, Everson GT
Hepatology. 2012;55:1620-1628

Abstract

Protease Inhibitors and Drug Interactions

Adding a protease inhibitor to ribavirin and interferon has transformed the treatment paradigm for HCV. However, it has also added complexity, adverse effects, and concern about drug interactions.

Kiser and colleagues review the major drug interactions of telaprevir and boceprevir and suggest approaches to managing these interactions for special populations, including patients with HCV infection after liver transplantation as well as patients with HIV and HCV coinfection.

Viewpoint

This is an excellent review of the implications of drug interactions of telaprevir and boceprevir and should be an invaluable reference for clinicians who use triple therapy to treat patients with HCV and special population subgroups in particular.

processing....